The Trump administration is negotiating with drugmakers to sell some of their obesity drugs via TrumpRx

The Trump administration is currently negotiating with pharmaceutical companies such as Novo Nordisk and Eli Lilly to offer some of their widely used obesity drugs through the TrumpRx program. These discussions aim to potentially expand access to effective weight-loss treatments by including them in Medicare and Medicaid coverage. While the negotiations are ongoing, the initiative reflects an effort to make these medications more affordable and accessible to a broader population. The potential expansion of coverage under federal health programs could represent a significant development in obesity treatment options for eligible patients. This move aligns with recent efforts to address obesity as a public health concern by leveraging existing healthcare frameworks. However, the final outcome of these negotiations and the extent of coverage expansion remain to be determined. The initiative underscores the administration's interest in collaborating with drugmakers to improve healthcare access.